Prognostic value of performance status assessed by patients themselves, nurses, and oncologists in advanced non-small cell lung cancer

Accuracy in the assessment of performance status by oncologists has not been well evaluated. We investigated possible discrepancies in the assessment of performance status among patients, nurses, and oncologists, and evaluated the prognostic importance of each assessment. Two hundred and six inpatients with inoperable, advanced non-small cell lung cancer were investigated prospectively. Weighted Kappa statistics for inter-observer agreement were 0.53 between oncologists and patients and 0.63 between oncologists and nurses. There was a significant difference among the assessments by the three groups (P < 0.001). Oncologists gave the healthiest performance status assessment, nurses an intermediate assessment, and patients the poorest. When included separately in the Cox model, the assessment by each group was significantly correlated with survival. However, the assessment by the patients themselves failed to distinguish survival of patients with performance status 1 and 2. Among the three models including patient-, nurse-, and oncologist-assessed PS, that including oncologist-assessed PS best fitted to the observed survival data. These results showed that the assessment by the patients themselves is different from those by the nurses and the oncologists and provided additional support for the use of the assessment by oncologists in clinical oncology. © 2001 Cancer Research Campaign http://www.bjcancer.com

[1]  N. Aaronson,et al.  ©1999 Cancer Research Campaign Article no. bjoc.1999.0655 , 2022 .

[2]  K. Rowland,et al.  Pre-treatment prognostic factors in stage III non-small cell lung cancer patients receiving combined modality treatment. , 1991, International journal of radiation oncology, biology, physics.

[3]  H. Hansen,et al.  Performance status assessment in cancer patients. An inter-observer variability study. , 1993, British Journal of Cancer.

[4]  J F Forbes,et al.  Prognostic value of quality-of-life scores during chemotherapy for advanced breast cancer. Australian New Zealand Breast Cancer Trials Group. , 1992, Journal of clinical oncology : official journal of the American Society of Clinical Oncology.

[5]  M. Citron,et al.  Combination chemotherapy for metastatic or recurrent carcinoma of the breast--a randomized phase III trial comparing CAF versus VATH versus VATH alternating with CMFVP: Cancer and Leukemia Group B Study 8281. , 1995, Journal of clinical oncology : official journal of the American Society of Clinical Oncology.

[6]  M. Bychkov,et al.  [Chemotherapy of lung cancer]. , 1972, Voprosy onkologii.

[7]  W. Gregory,et al.  Who should measure quality of life, the doctor or the patient? , 1988, British Journal of Cancer.

[8]  D. Ettinger,et al.  A randomized trial of the four most active regimens for metastatic non-small-cell lung cancer. , 1986, Journal of clinical oncology : official journal of the American Society of Clinical Oncology.

[9]  C. Mountain,et al.  Revisions in the International System for Staging Lung Cancer. , 1997, Chest.

[10]  Jacob Cohen,et al.  Weighted kappa: Nominal scale agreement provision for scaled disagreement or partial credit. , 1968 .

[11]  J. E. Brazier,et al.  Validating the SF-36 health survey questionnaire: new outcome measure for primary care. , 1992, BMJ.

[12]  H C van Houwelingen,et al.  Comparison of the predictive power of different prognostic indices for overall survival in patients with advanced ovarian carcinoma. , 1990, Cancer research.

[13]  Ian N. Olver,et al.  Observer error in grading performance status in cancer patients , 1999, Supportive Care in Cancer.

[14]  A Coulter,et al.  Short form 36 (SF36) health survey questionnaire: normative data for adults of working age. , 1993, BMJ.

[15]  P. Andersen,et al.  Prognostic factors in small cell lung cancer: multivariate model based on 778 patients treated with chemotherapy with or without irradiation. , 1986, Cancer research.

[16]  C. Presant Quality of life in cancer patients. Who measures what? , 1984, American journal of clinical oncology.

[17]  P. Ganz,et al.  Karnofsky performance status revisited: reliability, validity, and guidelines. , 1984, Journal of clinical oncology : official journal of the American Society of Clinical Oncology.

[18]  Jacob Cohen A Coefficient of Agreement for Nominal Scales , 1960 .

[19]  P. Novotny,et al.  Prospective evaluation of prognostic variables from patient-completed questionnaires. North Central Cancer Treatment Group. , 1994, Journal of clinical oncology : official journal of the American Society of Clinical Oncology.

[20]  C. Conill,et al.  Performance status assessment in cancer patients , 1990, Cancer.

[21]  T. Hutchinson,et al.  Scientific problems in clinical scales, as demonstrated in the Karnofsky index of performance status. , 1979, Journal of chronic diseases.

[22]  J. Yates,et al.  Evaluation of patients with advanced cancer using the karnofsky performance status , 1980, Cancer.

[23]  P. Fayers,et al.  Health-related quality of life in the general Norwegian population assessed by the European Organization for Research and Treatment of Cancer Core Quality-of-Life Questionnaire: the QLQ=C30 (+ 3). , 1998, Journal of clinical oncology : official journal of the American Society of Clinical Oncology.

[24]  D. Osoba Lessons learned from measuring health-related quality of life in oncology. , 1994, Journal of clinical oncology : official journal of the American Society of Clinical Oncology.

[25]  David R. Cox,et al.  Regression models and life tables (with discussion , 1972 .

[26]  E. McFadden,et al.  Toxicity and response criteria of the Eastern Cooperative Oncology Group , 1982, American journal of clinical oncology.

[27]  D. Karnofsky,et al.  The use of the nitrogen mustards in the palliative treatment of carcinoma. With particular reference to bronchogenic carcinoma , 1948 .

[28]  A. Buist,et al.  Characteristics of patients with asthma within a large HMO: A comparison by age and gender , 1998 .

[29]  A. Favero,et al.  Intra and interobserver variability in cancer patients' performance status assessed according to Karnofsky and ECOG scales. , 1991, Annals of oncology : official journal of the European Society for Medical Oncology.